Analyst Ratings January 28, 2026

Benchmark lifts Plexus price target to $195, cites multiple demand tailwinds

Research firm keeps Buy rating as Plexus heads into fiscal Q1 results with favorable valuation and solid balance-sheet signals

By Ajmal Hussain PLXS
Benchmark lifts Plexus price target to $195, cites multiple demand tailwinds
PLXS

Benchmark raised its 12-month price target on Plexus (NASDAQ: PLXS) to $195 from $165 and maintained a Buy rating ahead of the company’s fiscal first-quarter earnings release. The stock, trading at $173.51, has climbed 18% year-to-date and is trading close to a 52-week peak of $186.47. Benchmark highlighted several demand drivers and reiterated management’s growth confidence while noting an outlook slightly above consensus.

Key Points

  • Benchmark raised its Plexus price target to $195 from $165 and retained a Buy rating ahead of fiscal Q1 results.
  • Plexus was trading at $173.51, up 18% year-to-date and near a 52-week high of $186.47; market cap stands at $4.64 billion with a Piotroski Score of 9.
  • Benchmark cited recovery across end markets, stronger semiconductor capital equipment demand, and improving Boeing production trends as potential growth drivers, and sees a longer-term multi-sector growth cycle including aerospace, defense, space, and medical inventory dynamics.

Benchmark increased its price objective for Plexus (NASDAQ: PLXS) to $195.00, up from $165.00, and kept a Buy recommendation as the electronics manufacturing services provider prepares to report fiscal first-quarter results. The company was trading at $173.51 at the time of the update, reflecting an 18% gain so far this year and trading near its 52-week high of $186.47.

Plexus is set to disclose quarterly results after the market close on Wednesday, with a follow-up conference call scheduled for Thursday morning. The company carries a market capitalization of $4.64 billion and, according to InvestingPro data cited in the research note, registers a Piotroski Score of 9.

Benchmark signaled expectations that reported results will be largely consistent with current estimates, while management’s commentary could edge the outlook modestly above consensus. The research firm also pointed to Plexus’s PEG ratio of 0.48 as evidence that the stock may be trading at an attractive valuation relative to its expected growth rate.

In its analysis, Benchmark identified several potential sources of revenue upside. These include continued recovery across end markets, a strengthening in semiconductor capital equipment demand, and improving production trends at Boeing that could contribute positively to guidance. Over a longer horizon, the firm believes Plexus could enter what it describes as a "durable, long tailed growth cycle." That longer-term view is predicated on market share gains and improving demand across semiconductor capital equipment, commercial aerospace, defense, and space sectors, together with more favorable inventory dynamics in the medical segment.

The research note frames these industry and end-market developments as potential catalysts that could support Plexus’s revenue trajectory and valuation. Benchmark’s maintained Buy rating and higher price target reflect the firm’s assessment of both near-term stability around the upcoming quarter and a multi-sector demand backdrop that could underpin longer-term growth.

Investors will be watching the post-close release and the subsequent conference call for confirmation of management’s tone and any guidance revisions that might validate Benchmark’s modestly improved outlook.

Risks

  • Results could deviate from expectations - while Benchmark expects largely in-line results, any weaker-than-expected quarter or less confident management commentary could alter the outlook. This risk affects equity investors and the broader manufacturing sector.
  • Dependence on end-market recovery and semiconductor capital equipment demand - if these demand drivers do not strengthen as anticipated, Plexus’s upside to guidance may be limited. This uncertainty impacts the semiconductor supply chain and electronics manufacturing services.
  • Exposure to aerospace trends - anticipated benefits from improving Boeing production are cited as a potential upside, but changes in aerospace production dynamics could introduce variability for commercial aerospace and defense revenue streams.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026